Ningbo MedicalSystem Biotechnology Co Ltd (300439) — Working Capital to Net Assets Ratio
Ningbo MedicalSystem Biotechnology Co Ltd (300439) has a Working Capital to Net Assets ratio of 43.3% as of September 2025. Working capital of CN¥1.28 Billion (current assets of CN¥1.88 Billion minus current liabilities of CN¥602.92 Million) is measured against net assets of CN¥2.95 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Ningbo MedicalSystem Biotechnology Co Lt (300439) balance sheet quality index to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Ningbo MedicalSystem Biotechnology Co Ltd Working Capital to Net Assets (2011–2024)
This chart shows how Ningbo MedicalSystem Biotechnology Co Ltd's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2011 to 2024. As of September 2025, the ratio stands at 43.3%, reflecting working capital of CN¥1.28 Billion against net assets of CN¥2.95 Billion CNY. Check Ningbo MedicalSystem Biotechnology Co Lt tangible book value ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Ningbo MedicalSystem Biotechnology Co Ltd (2011–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Ningbo MedicalSystem Biotechnology Co Ltd from 2011 to 2024, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 300439 stock market capitalisation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 39.4% | CN¥1.16 Billion | CN¥2.93 Billion | CN¥1.82 Billion | CN¥667.44 Million | ▼ -4.9 pp |
| 2023 | 44.3% | CN¥1.20 Billion | CN¥2.71 Billion | CN¥1.90 Billion | CN¥699.13 Million | ▲ +1.1 pp |
| 2022 | 43.3% | CN¥1.09 Billion | CN¥2.52 Billion | CN¥2.07 Billion | CN¥981.30 Million | ▲ +3.6 pp |
| 2021 | 39.7% | CN¥948.74 Million | CN¥2.39 Billion | CN¥2.01 Billion | CN¥1.06 Billion | ▲ +29.0 pp |
| 2020 | 10.7% | CN¥180.40 Million | CN¥1.69 Billion | CN¥1.57 Billion | CN¥1.39 Billion | ▲ +5.5 pp |
| 2019 | 5.2% | CN¥72.07 Million | CN¥1.39 Billion | CN¥2.13 Billion | CN¥2.06 Billion | ▼ -4.5 pp |
| 2018 | 9.7% | CN¥221.10 Million | CN¥2.27 Billion | CN¥2.38 Billion | CN¥2.16 Billion | ▼ -17.3 pp |
| 2017 | 27.0% | CN¥618.37 Million | CN¥2.29 Billion | CN¥2.40 Billion | CN¥1.78 Billion | ▼ -7.5 pp |
| 2016 | 34.5% | CN¥630.99 Million | CN¥1.83 Billion | CN¥1.76 Billion | CN¥1.13 Billion | ▼ -44.4 pp |
| 2015 | 78.9% | CN¥1.02 Billion | CN¥1.29 Billion | CN¥1.14 Billion | CN¥128.29 Million | ▲ +21.9 pp |
| 2014 | 57.0% | CN¥236.66 Million | CN¥415.13 Million | CN¥432.37 Million | CN¥195.71 Million | ▲ +6.2 pp |
| 2013 | 50.8% | CN¥156.66 Million | CN¥308.32 Million | CN¥314.75 Million | CN¥158.09 Million | ▲ +6.5 pp |
| 2012 | 44.3% | CN¥89.76 Million | CN¥202.58 Million | CN¥216.42 Million | CN¥126.66 Million | ▲ +5.9 pp |
| 2011 | 38.4% | CN¥42.59 Million | CN¥110.84 Million | CN¥110.76 Million | CN¥68.17 Million | — |